Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Science Immunology(2020)10.1126/sciimmunol.abe0367Source: DataRank Database

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients is a research paper published in Science Immunology (2020). On theSindex it has a DataRank of 16.2. It has been cited 691 times, with 200 citing works in its 1-hop citation network.

N/A

16.2DataRank · unranked

Scored on demand from live citation data

Open Access691 citations · 200 citing works in its network

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 15.55)OA: hybridTopics (68)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 6%Citation Network 94%

Base Score Contribution

0.981

From this paper's citation signal

Citation Network Contribution

15.2

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
Signal Transduction and Targeted Therapy2021135 citations5 referencesContributes 0.983
Endemic SARS-CoV-2 will maintain post-pandemic immunity
Nature reviews. Immunology202181 citations11 referencesContributes 0.401
SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands
Open Forum Infectious Diseases202121 citations8 referencesContributes 0.386
Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020
Eurosurveillance202278 citations14 referencesContributes 0.312
A case of COVID-19 reinfection in the UK
Clinical Medicine202074 citations15 referencesContributes 0.288

Authors (35)

Forrest K. Jones ORCID,Ariana Nodoushani ORCID,Meagan Kelly,Margaret Becker ORCID,Damien Slater ORCID

Live enrichment

PubMed:33033172 PMC:PMC7857394 OpenAlex:https://openalex.org/W3092301564

National Institutes of Health

Grant: R01 AI146779

National Institutes of Health

Grant: T32 GM007753

National Institutes of Health

Grant: T32 AI007245

Centers for Disease Control and Prevention

Grant: U01CK000490

NIH HHS

Grant: R01 T32GM007753

NIAID NIH HHS

Grant: R01 AI135115

NIGMS NIH HHS

Grant: T32 GM008313

National Institutes of Health

Grant: 5U01CK000490-03

Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs

National Institutes of Health

Grant: 1F32GM013039-01

MOLECULAR ANALYSIS OF THE YEAST HEAT SHOCK TRANSCRIPTION

National Institutes of Health

Grant: 3R01AI146779-01S1

Epitope focusing to the receptor binding motif for a universal coronavirus vaccine

National Institutes of Health

Grant: 3T32GM007753-41S1

Medical Scientist Training Program

National Institutes of Health

Grant: 5T32AI007245-25

Molecular Basis of Viral Infectivity

National Institutes of Health

Grant: 5R01AI135115-02

Estimating Cholera Burden with Cross-sectional Immunologic Data

MassCPR

FWCI

15.55

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1126/sciimmunol.abe0367

publisherhttps://doi.org/10.1126/sciimmunol.abe0367

publisherhttps://syndication.highwire.org/content/doi/10.1126/sciimmunol.abe0367

publisherhttps://www.science.org/doi/pdf/10.1126/sciimmunol.abe0367

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33033172

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Protein DomainsBetacoronavirusCOVID-19SARS-CoV-2AdultAgedAntibodies, ViralCross ReactionsFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMaleMiddle AgedPneumonia, ViralCohort StudiesBiomarkersCoronavirus InfectionsAntibodies, NeutralizingPandemicsDried Blood Spot TestingSpike Glycoprotein, Coronavirus

Keywords

AntibodySeroconversionImmunologyVirologyIsotypeTiterImmunoglobulin GCoronavirusBiologyPersistence (discontinuity)Spike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)Internal medicineMonoclonal antibodyDiseaseInfectious disease (medical specialty)AdultMalePneumonia, ViralCross ReactionsAntibodies, ViralCohort StudiesBetacoronavirusHumansPandemicsAgedCOVID-19General MedicineMiddle AgedAntibodies, NeutralizingImmunoglobulin AImmunoglobulin MFemaleDried Blood Spot TestingCoronavirus InfectionsBiomarkersReports

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Individually optimal choices can be collectively disastrous in COVID-19 disease control

10.6084/m9.figshare.14524726.v1figshare

Additional file 1 of Individually optimal choices can be collectively disastrous in COVID-19 disease control

10.6084/m9.figshare.14524726figshare

Additional file 1 of Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

10.6084/m9.figshare.16633017.v1figshare

Additional file 1 of Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

10.6084/m9.figshare.16633017figshare

Additional file 1 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.25834137.v1figshare

Additional file 1 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.25834137figshare

Additional file 2 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.25834271.v1figshare

Additional file 2 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.25834271figshare

Additional file 3 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.26721078.v1figshare

Additional file 3 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.26721078figshare

Additional file 4 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.26721081.v1figshare

Additional file 4 of Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022

10.6084/m9.figshare.26721081figshare